Vemurafenib

Generic Name
Vemurafenib
Brand Names
Zelboraf
Drug Type
Small Molecule
Chemical Formula
C23H18ClF2N3O3S
CAS Number
918504-65-1
Unique Ingredient Identifier
207SMY3FQT
Background

Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collab...

Indication

Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E. The V600E mutation, a substitution of glutamic acid for valine, accounts for 54% of the cases of cutaneous melanoma.
...

Associated Conditions
Metastatic Melanoma, Refractory Lung Non-Small Cell Carcinoma, Unresectable Melanoma, Refractory Erdheim-Chester disease
Associated Therapies
-
Clinical Trials
Related News

A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers

First Posted Date
2012-02-02
Last Posted Date
2017-11-20
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
208
Registration Number
NCT01524978
Locations
🇫🇷

Centre Georges François Leclerc, Dijon, France

🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

🇺🇸

Arizona Oncology, Tucson, Arizona, United States

and more 31 locations

BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Phase 1
Terminated
Conditions
Malignant Melanoma
Interventions
Drug: vemurafenib
First Posted Date
2012-01-26
Last Posted Date
2016-10-10
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
6
Registration Number
NCT01519323

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

First Posted Date
2011-12-21
Last Posted Date
2017-10-24
Lead Sponsor
Melanoma Research Foundation Breakthrough Consortium
Target Recruit Count
10
Registration Number
NCT01495988
Locations
🇺🇸

Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States

🇺🇸

The Angeles Clinic, Los Angeles, California, United States

🇺🇸

Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., District of Columbia, United States

and more 11 locations

Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation

Phase 2
Terminated
Conditions
Melanoma
Interventions
Drug: vemurafenib
First Posted Date
2011-11-18
Last Posted Date
2015-11-18
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
2
Registration Number
NCT01474551
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)

Phase 1
Terminated
Conditions
Melanoma
Interventions
Drug: Ipilimumab (BMS-734016)
Drug: Vemurafenib
First Posted Date
2011-07-22
Last Posted Date
2015-01-01
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
18
Registration Number
NCT01400451
Locations
🇺🇸

University Of California Los Angeles, Los Angeles, California, United States

🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

🇺🇸

Dana Farber Cancer Inst, Boston, Massachusetts, United States

and more 1 locations

A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases

Phase 2
Completed
Conditions
Malignant Melanoma
Interventions
Drug: Vemurafenib
First Posted Date
2011-06-23
Last Posted Date
2016-08-01
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
146
Registration Number
NCT01378975

A Study of Vemurafenib in Participants With Metastatic Melanoma

Phase 3
Completed
Conditions
Malignant Melanoma
Interventions
Drug: Vemurafenib
First Posted Date
2011-03-02
Last Posted Date
2017-12-18
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
3219
Registration Number
NCT01307397
Locations
🇦🇱

University "Mother Theresa" Hospital Center; Oncology Department, Tirana, Albania

🇦🇷

Hospital Britanico; Oncologia, Buenos Aires, Argentina

🇦🇷

Fundación CIDEA, Buenos Aires, Argentina

and more 277 locations

A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation

Phase 2
Completed
Conditions
Neoplasms
Interventions
Drug: Vemurafenib
First Posted Date
2011-01-31
Last Posted Date
2016-09-07
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
51
Registration Number
NCT01286753

A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma

Phase 1
Completed
Conditions
Malignant Melanoma
Interventions
Drug: Cobimetinib
Drug: vemurafenib
First Posted Date
2011-01-07
Last Posted Date
2019-07-29
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
131
Registration Number
NCT01271803
Locations
🇺🇸

The Angeles Clinic and Research Institute, Santa Monica Office, Santa Monica, California, United States

🇺🇸

UCLA Department of Medicine, Los Angeles, California, United States

🇺🇸

University of California at San Francisco, San Francisco, California, United States

and more 7 locations

A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)

Phase 3
Completed
Conditions
Malignant Melanoma
Interventions
Drug: Vemurafenib
Drug: Dacarbazine
First Posted Date
2009-11-03
Last Posted Date
2016-09-28
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
675
Registration Number
NCT01006980
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy